BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Morning Overview on MSN
A cancer drug just became the first FDA-cleared treatment for a common breast-cancer subtype
Patients with the most common molecular subtype of advanced breast cancer now have a targeted drug approved specifically for ...
Celcuity said Revtorpyk is the first drug of its kind to receive FDA approval. "The PI3K/AKT/mTOR, or PAM, pathway is one of the most important targets in cancer, but comprehensiv ...
Breast cancer treatment has been a showcase of increasing precision—from surgery and chemotherapy, to endocrine therapies and targeted treatments. Breast cancer subtypes can be defined by expression ...
Serabelisib (KP-001) was filed with Japan's regulatory authority in May as a therapy for the treatment of vascular ...
REVTORPYK (gedatolisib) vial and box REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In the Phase 3 ...
A new research perspective was published in Volume 13 of Oncoscience on June 3, 2026, titled "The dual axis of tumorigenesis: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results